Expression of protein tyrosine kinase 6 (PTK6) in nonsmall cell lung cancer and their clinical and prognostic significance

  title={Expression of protein tyrosine kinase 6 (PTK6) in nonsmall cell lung cancer and their clinical and prognostic significance},
  author={Chao Zhao and Yan Chen and Weiwei Zhang and Jianrong Zhang and Yu-lian Xu and Wenjie Li and Sun-xiao Chen and Anmei Deng},
  journal={OncoTargets and therapy},
  pages={183 - 188}
Aim: The aim of the study was to validate the expression of protein tyrosine kinase 6 (PTK6) in nonsmall cell lung cancer (NSCLC), and to evaluate its clinicopathological and prognostic significance. Methods: We first conducted a meta-analysis on the mRNA profiling data sets of NSCLC in the Oncomine database. Then, one of the most significantly upregulated tyrosine kinase targets, PTK6, was further validated by immunohistochemistry in 104 primary NSCLC tumors. Furthermore the association… 

Figures and Tables from this paper

Prognostic value of protein tyrosine kinase 6 overexpression in cancers: a meta-analysis.
PTK 6 expression in tumor was a prognostic factor in patients with various cancers, but the direction of prognosis differs, depending on the degree of PTK6 expression in non-tumor tissues.
Downregulated expression of PTK6 is correlated with poor survival in esophageal squamous cell carcinoma
To investigate the clinical prognostic value of protein tyrosine kinase 6 (PTK6) in patients with esophageal squamous cell carcinoma, quantitative RT-PCR and Western blotting and multivariate Cox regression analysis demonstrated that the expression level of PTK6 is an independent prognostic factor in ESCCs.
The expression and prognostic value of protein tyrosine kinase 6 in early-stage cervical squamous cell cancer
PTK6 is overexpressed in cervical squamous cell cancer and increased PTK6 expression is associated with reduced 5-year overall survival and is an independent prognostic predictor for cervical cancer.
Aberrant expression of Notch3 predicts poor survival for hepatocellular carcinomas.
It is confirmed that Notch3 is overexpressed in HCC tissues compared with normal liver tissues, and a high expression level of notch3 was significantly associated with bigger tumor size, multiple tumors, late tumor-node-metastasis stage and shorter overall survival.
Targeting protein tyrosine kinase 6 in cancer.
PTK6 promotes hepatocellular carcinoma cell proliferation and invasion.
It is demonstrated that the PTK6 expression was upregulated in HCC tissues compared with adjacent normal tissues, and this suggested thatPTK6 played an oncogene role in the development of HCC.
Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancer
PTK6 is overexpressed in CRC tissues and plays a stimulatory role in the proliferation and chemoresistance of CRC cells both in vitro and in vivo and PTK6 interacts with JAK2 and phosphorylates it to activate JAK1/STAT3 signaling to promote the stemness and chemorsistance of HRC cells.
Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer
Data indicate that PTK6 has complex, context-specific functions in colon cancer;PTK6 promotes the epithelial phenotype to antagonize the EMT in a kinase-independent manner, whereas activation of PTK 6 promotes oncogenic signaling.
PTK6 Promotes Cancer Migration and Invasion in Pancreatic Cancer Cells Dependent on ERK Signaling
The results suggest that PTK6 regulates cellular migration and invasion in pancreatic cancer via ERK signaling, and may be a novel therapeutic target for Pancic cancer.
Cancer-Associated Mutations in Breast Tumor Kinase/PTK6 Differentially Affect Enzyme Activity and Substrate Recognition.
Biochemical data suggest that several of the mutations activate Brk by disrupting intramolecular interactions that normally maintain Brk in an autoinhibited conformation, and differential effects on recognition and phosphorylation of substrates are observed, suggesting that the mutations can influence downstream Brk signaling by multiple mechanisms.


Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients
It is suggested that PTK6 may serve as a future target for the development of novel treatments in breast cancer after a retrospective study performed on 426 archival breast cancer samples from patients with long-term follow-up suggested that it is of significant prognostic value in the outcome of breast carcinomas.
Detection of Brk expression in non-small cell lung cancer: clinicopathological relevance
The present findings indicate an increase of cytoplasmic Brk expression in NSCLC which may play a role in tumor development, including tumor expansion and lymph node metastasis in which Ki67, but not E-cadherin, and P53 status may be involved.
Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma
It is concluded that whereas altered expression of DDRs may contribute to malignant progression of NSCLC, it is unlikely that this results from mutations in the DDR1 and DDR2 genes that were investigated.
Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung carcinomas.
Findings indicate that up-regulation of DDR1 may contribute to the progression and poor prognosis of NSCLC and this effect may be associated with increased invasiveness.
Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival Prediction
The gene signatures identified are promising tools for histo-pathological classification of non-small cell lung cancer, and may improve the prediction of clinical outcome.
Gene Expression Signature of Cigarette Smoking and Its Role in Lung Adenocarcinoma Development and Survival
This work provides insight into the smoking-related mechanisms of lung neoplasia, and shows that the very mitotic genes known to be involved in cancer development are induced by smoking and affect survival.
The Brk protein tyrosine kinase as a therapeutic target in cancer: opportunities and challenges
A potentially kinase-independent role for Brk in regulating proliferation suggests that alternative approaches, such as inhibiting protein–protein interactions, may prove more successful in the development of novel cancer therapies.
Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation
RNA interference is used to efficiently and specifically downregulate Brk protein levels in breast carcinoma cells, and this results in a significant suppression of their proliferation, identifying Brk as a novel target for antiproliferative therapy in the majority of breast cancers.
A training-testing approach to the molecular classification of resected non-small cell lung cancer.
  • N. Yamagata, Y. Shyr, D. Carbone
  • Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
Results demonstrate that gene expression profiling can identify molecular classes of resected NSCLCs that correctly classifies a blinded test cohort, and correlates with and supplements standard histological evaluation.
Gene-expression profiles predict survival of patients with lung adenocarcinoma
The identification of a set of genes that predict survival in early-stage lung adenocarcinoma allows delineation of a high-risk group that may benefit from adjuvant therapy.